Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

Inclusion Criteria: * ECOG WHO Performance status = 0 or 1 * Signed and dated informed consent * Patients with histological diagnosis of oesogastric or pancreatic adenocarcinoma * Resectable tumors * Patients able to have a laparoscopy * In case of absence of peritoneal invasion on the laparoscopy, patient candidate to a chemotherapy schedule by FLOT or FOLFOX in perioperative setting for oesogastric adenocarcinoma, or FOLFIRINOX in perioperative setting for pancreatic adenocarcinoma * Registration in a national health care system (CMU included) * Patient speak and understand the french Exclusion Criteria: * Histology other than adenocarcinoma * Metastatic disease * History of previous treatment with oxaliplatine * History of systemic chemotherapy administration within 5 years prior to inclusion, * Patient with an non balanced progressive condition/disease (liver failure, renal failure (creatinine clearance \<30mL/min), respiratory failure, congestive heart failure, myocardial infarction in the last 6 months, etc.), * Patient on curative dose anticoagulant, * Patient with complete dihydropyrimidine dehydrogenase deficiency (Uracilemia ≥ 150 ng/ml), * Patient not operable for the pathology concerned, * Pregnant or breastfeeding woman, woman of childbearing age who has not performed a pregnancy test before the procedure, * Patient with legal incapacity (person deprived of liberty or under curatorship, stutorship, safeguard of justice), * Patient who, for psychiatric, social, family or geographical reasons, cannot be followed and/or comply with the requirements of the study,, * Discovery of peritoneal invasion during the peritoneal exploratory of the laparoscopy